Galderma Group AGGDERF +16.71%21 EV-to-FCF is 60.29 as of Jun. 29, 2026, which is 67% below its 10-year median of 180.23. GuruFocus rates GDERF with a GF Score™ of 21/100. The stock has 4 warning signs investors should review. Among 559 Drug Manufacturers companies, Galderma Group AG ranks worse than 75.67% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Galderma Group AG's Enterprise Value is $62,162 Mil.
Galderma Group AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $1,031 Mil. Therefore, Galderma Group AG's EV-to-FCF for today is 60.29.
The historical rank and industry rank for Galderma Group AG's EV-to-FCF or its related term are showing as below:
GDERF'
s EV-to-FCF Range Over the Past 10 Years
Min: 42.9 Med: 180.23 Max: 2676.69
Current: 60.29
During the past 5 years, the highest EV-to-FCF of Galderma Group AG was 2676.69. The lowest was 42.90. And the median was 180.23.
GDERF's EV-to-FCF is ranked worse than 75.67% of 559
companies
in the Drug Manufacturers industry
Industry Median: 20.02
vs GDERF: 60.29
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Galderma Group AG (OTCPK:GDERF) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Galderma Group AG's PE Ratio (TTM) for today is calculated as:
Galderma Group AG's share price for today is $245.97.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Galderma Group AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $2.580.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Galderma Group AG EV-to-FCF Related Terms
Galderma Group AG EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Galderma Group AG's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galderma Group AG EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Galderma Group AG's EV-to-FCF falls into.
Galderma Group AG's current Enterprise Value is $62,162 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Galderma Group AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $1,031 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galderma Group AG (GDERF) has a EV-to-FCF of 60.29 as of Jun. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Galderma Group AG and its competitors. This is 67% below median its historical median of 180.23. Over the past decade, Galderma Group AG's EV-to-FCF has ranged from 42.90 to 2,676.69. According to the industry distribution chart, Galderma Group AG ranks #423 out of 559 companies in the Drug Manufacturers industry, placing it in the top 75.7%.
Is Galderma Group AG's EV-to-FCF too high?
Galderma Group AG's current EV-to-FCF of 60.29 is 67% below median its 10-year median of 180.23. Over the past 10 years, this metric has ranged from a low of 42.90 to a high of 2,676.69. The Drug Manufacturers industry median EV-to-FCF is 20.02. Galderma Group AG's value of 60.29 is 201.1% above this industry median. Based on the distribution chart, Galderma Group AG ranks #423 out of 559 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Galderma Group AG has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Galderma Group AG ranks #423 out of 559 companies for EV-to-FCF. This places Galderma Group AG in the lower half of its industry. The industry median EV-to-FCF is 20.02. Galderma Group AG's value of 60.29 is 201.1% above this benchmark. Historically, Galderma Group AG's own EV-to-FCF has ranged from 42.90 to 2,676.69 over the past decade. While the company's 10-year median is 180.23 vs. the industry median of 20.02, Galderma Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.02, based on 559 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galderma Group AG's current EV-to-FCF of 60.29 is 201.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Galderma Group AG and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galderma Group AG's current EV-to-FCF is 60.29, which is 67% below median its own 10-year median of 180.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (GDERF) has a current EV-to-FCF of 60.29. The current EV-to-FCF is 60.29, which is 67% below median its 10-year median of 180.23 and 201.1% above the Drug Manufacturers industry median of 20.02. Galderma Group AG's overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Galderma Group AG (GDERF), the current EV-to-FCF is 60.29 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
21GF Score
Get the complete analysis for GDERF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GDERF has been successfully added to your 